REFERENCES
1. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of Patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793-867.
2. Behr E, Wood D, Wright M, et al. Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome. The Lancet. 2003;362:1457-9.
3. Raju H, Behr ER. Unexplained sudden death, focussing on genetics and family phenotyping. Curr Opin Cardiol. 2013;28:19-25.
4. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138.
5. Wu Q, Zhang L, Zheng J, et al. Forensic pathological study of 1656 cases of sudden cardiac death in southern China. Medicine (Baltimore). 2016;95:e2707.
6. Hua W, Zhang L, Wu Y, et al. Incidence of sudden cardiac death in China. J Am Coll Cardiol. 2009;54:1110-8.
7. Basso C, Aguilera B, Banner J, et al. ; on behalf of the Association for European Cardiovascular Pathology. Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology. Virchows Arch. 2017;471:691-705.
8. Holm PH, Jensen THL, Westaby J, et al. quantitative histological insights into sudden arrhythmic death syndrome: findings from a forensic autopsy cohort. APMIS. 2026;134:e70169.
9. Fialho GL, Wolf P, Walz R, Lin K. SUDEP - more attention to the heart? A narrative review on molecular autopsy in epilepsy. Seizure. 2021;87:103-6.
10. Stiles MK, Wilde AA, Abrams DJ, et al. 2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Heart Rhythm. 2021;18:e1-e50.
11. Tseng ZH, Olgin JE, Vittinghoff E, et al. Prospective countywide surveillance and autopsy characterization of sudden cardiac death: POST SCD study. Circulation. 2018;137:2689-700.
12. Pouleur A, Barkoudah E, Uno H, et al. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation. 2010;122:597-602.
14. Barranco R, Caristo I, Molinelli A, Rocca G, Vernazza N, Ventura F. Update on the similarities between SADS, SIDS, and SUDEP: three sides of the same pyramid? Int J Legal Med. 2025;140:1-12.
15. Lou J, Chen H, Huang S, Chen P, Yu Y, Chen F. Update on risk factors and biomarkers of sudden unexplained cardiac death. J Forensic Leg Med. 2022;87:102332.
16. Huang S, Chen J, Song M, et al. Whole-exome sequencing and electrophysiological study reveal a novel loss-of-function mutation of KCNA10 in epinephrine provoked long QT syndrome with familial history of sudden cardiac death. Leg Med. 2023;62:102245.
17. Sheng M, Zheng H, Zhang L, et al. SCN5A c.4720G> A: a rare genetic variant associated with familial sick sinus syndrome and sudden cardiac death. Int J Legal Med. 2026;140:1951-62.
18. Huang S, Zhang J, Wan H, et al. Plasma extracellular vesicles microRNA-208b-3p and microRNA-143-3p as novel biomarkers for sudden cardiac death prediction in acute coronary syndrome. Molecular Omics. 2023;19:262-73.
19. Lou J, Cao Y, Yu Y, et al. Investigation of heart lipid changes in acute β-AR activation-induced sudden cardiac death by time-of-flight secondary ion mass spectrometry. Analyst. 2020;145:5889-96.
20. Wan H, Huang S, Duan J, et al. Endogenous pyruvate and lactic dehydrogenase B in plasma extracellular vehicles predict sudden cardiac death risk in acute coronary syndrome: A multiomics study. Asian Heart J. 2026;2:14-25.
21. Femia G, Langlois N, Raleigh J, et al. Comparison of conventional autopsy with post-mortem magnetic resonance, computed tomography in determining the cause of unexplained death. Forensic Sci Med Pathol. 2021;17:10-8.
22. Solomon N, Gascho D, Adolphi NL, et al. The evolution of postmortem investigation: a historical perspective on autopsy's decline and imaging’s role in its revival. Front Radiol. 2025;5:1565012.
23. Tortosa Lopez JM. Histopathology in medico-legal autopsies: clinical foundation, legal mandate, and judicial guarantee. J Forensic Leg Med. 2025;115:102974.
24. Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults. J Am Coll Cardiol. 2011;58:1254-61.
25. Garcia-Elias A, Benito B. Ion channel disorders and sudden cardiac death. Int J Mol Sci. 2018;19:692.
26. Sieira J, Dendramis G, Brugada P. Pathogenesis and management of Brugada syndrome. Nat Rev Cardiol. 2016;13:744-56.
27. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease. J Am Coll Cardiol. 2019;73:e81-e192.
28. Chinese Society of Pathology, Chinese Medical Association Cardiovascular Disease Group of the Chinese Society of Pathology, Chinese Medical Association, et al. Chinese expert consensus statement on the autopsy and molecular diagnosis of sudden cardiac death. Chin Circ J. 2022;37:865-75.
29. Campuzano O, Tirón C, Martínez-barrios E, et al. The role of molecular autopsy in concealed cardiomyopathies. Genes. 2025;16:1273.
30. Isbister JC, Nowak N, Butters A, et al. “Concealed cardiomyopathy” as a cause of previously unexplained sudden cardiac arrest. Int J Cardiol. 2021;324:96-101.
31. Isbister JC, Nowak N, Yeates L, et al. Concealed cardiomyopathy in autopsy-inconclusive cases of sudden cardiac death and implications for families. J Am Coll Cardiol. 2022;80:2057-68.
32. Coll M, Alcalde M, Fernández-Falgueras A, et al. Value of molecular autopsy in suspected sudden cardiac death in the young. J Mol Diagn. 2025;27:859-68.
33. Delpire B, Dilling-Boer D, Ghekiere O, et al. Electroanatomical mapping may identify concealed arrhythmogenic cardiomyopathy in endurance athletes with complex ventricular arrhythmias. JACC: Case Reports. 2026;31:107493.
34. Tu E, Bagnall RD, Duflou J, Semsarian C. Post-mortem review and genetic analysis of sudden unexpected death in epilepsy (SUDEP) Cases. Brain Pathol. 2010;21:201-8.
35. Ruthirago D, Julayanont P, Karukote A, Shehabeldin M, Nugent K. Sudden unexpected death in epilepsy: ongoing challenges in finding mechanisms and prevention. Int J Neurosci. 2018;128:1052-60.
36. Farrell EK, Tang S, Feng H. Vanillin suppresses seizure-induced mortality in the DBA/1 mouse model of SUDEP. Neurosci Lett. 2026;877:138575.
37. Ryvlin P, Rheims S. SUDEP update 2026: recent advances in experimental and clinical research. Curr Opin Neurol. 2026;39:123-30.
38. Parisi P, Oliva A, Coll Vidal M, et al. Coexistence of epilepsy and Brugada syndrome in a family with SCN5A mutation. Epilepsy Res. 2013;105:415-8.
39. Bagnall RD, Crompton DE, Semsarian C. Genetic basis of sudden unexpected death in epilepsy. Front Neurol. 2017;8:348.
40. Chahal CAA, Tester DJ, Fayyaz AU, et al. Confirmation of cause of death via comprehensive autopsy and whole exome molecular sequencing in people with epilepsy and sudden unexpected death. JAHA. 2021;10:e021170.
41. Bagnall RD, Perucca P. ; for the ILAE Genetics Commission. ILAE genetic literacy series: postmortem genetic testing in sudden unexpected death in epilepsy. Epileptic Disord. 2023;25:472-9.
42. Brunklaus A, Feng T, Brünger T, et al. Gene variant effects across sodium channelopathies predict function and guide precision therapy. Brain. 2022;145:4275-86.
43. TASK FORCE ON SUDDEN INFANT DEATH SYNDROME. SIDS and Other sleep-related infant deaths: updated 2016 recommendations for a safe infant sleeping environment. Pediatrics. 2016;138:e20162938.
44. Goldstein RD, Blair PS, Sens MA, et al. ; The 3rd International Congress on Sudden Infant and Child Death. Inconsistent classification of unexplained sudden deaths in infants and children hinders surveillance, prevention and research: recommendations from The 3rd International Congress on Sudden Infant and Child Death. Forensic Sci Med Pathol. 2019;15:622-8.
45. Hakanen E, Oura P, Vauhkonen PK. Neuropathologic findings and age-related differences in Finnish pediatric medico-legal autopsies. J Forensic Sci. 2026;71:1246-54.
46. Kaler J, Hussain A, Lee S. Manifestation and pathogenesis of sudden infant death syndrome: a review. Crit Rev Eukaryot Gene Expr. 2020;30:111-20.
47. Bechtel K, Vincent GA, Sullivan B, Gaither J. Analysis of first and second sleep environments in unexplained sudden deaths in infants based on scene reenactment data. Am J Forensic Med Pathol. 2026;47:113-6.
48. Shapiro-Mendoza CK, Palusci VJ, Hoffman B, et al. ; AAP TASK FORCE ON SUDDEN INFANT DEATH SYNDROME, COUNCIL ON CHILD ABUSE AND NEGLECT, COUNCIL ON INJURY, VIOLENCE, AND POISON PREVENTION, SECTION ON CHILD DEATH REVIEW AND PREVENTION, NATIONAL ASSOCIATION OF MEDICAL EXAMINERS. Half century since SIDS: a reappraisal of terminology. Pediatrics. 2021;148:e2021053746.
49. Cazzato F, Coll M, Grassi S, et al. Investigating cardiac genetic background in sudden infant death syndrome (SIDS). Int J Legal Med. 2024;138:2229-37.
50. Argentiero G, Talamo M, Amirante F, Cecchetto G, Solarino B. Effects of decomposition on the cardiovascular system: a systematic review. Forensic Sci Int. 2025;373:112529.
51. Byard RW. Artefacts due to putrefactive gas production - an overview. Med Sci Law. 2024;65:65-70.
52. Van Den Bogaert W, Alders L, Wuestenbergs J, Dequeker E, Van De Voorde W. Defining, exploring the sources and expressing post-mortem diagnostic uncertainty. Forensic Sci Med Pathol. 2024;21:728-35.
53. Martínez-Barrios E, Grassi S, Brión M, et al. Molecular autopsy: twenty years of post-mortem diagnosis in sudden cardiac death. Front Med. 2023;10:1118585.
54. Goodwin S, Mcpherson JD, Mccombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016;17:333-51.
55. Castiglione V, Modena M, Aimo A, et al. Molecular autopsy of sudden cardiac death in the genomics era. Diagnostics. 2021;11:1378.
56. Salfati EL, Spencer EG, Topol SE, et al. Re-analysis of whole-exome sequencing data uncovers novel diagnostic variants and improves molecular diagnostic yields for sudden death and idiopathic diseases. Genome Med. 2019;11:83.
57. Semsarian C, Ingles J, Wilde AAM. Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. Eur Heart J. 2015;36:1290-6.
58. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011;8:1308-39.
59. Baudhuin LM, Lagerstedt SA, Klee EW, Fadra N, Oglesbee D, Ferber MJ. Confirming variants in next-generation sequencing panel testing by sanger sequencing. J Mol Diagn. 2015;17:456-61.
60. Adams DR, Eng CM. Next-generation sequencing to diagnose suspected genetic disorders. N Engl J Med. 2018;379:1353-62.
61. Shamseldin HE, Alabdi L, Maddirevula S, et al. ; Molecular Autopsy Consortium. Lethal variants in humans: lessons learned from a large molecular autopsy cohort. Genome Med. 2021;13:161.
62. Osouf J, Schalk A, Schaefer E, et al. Genetic testing after sudden death with negative ancillary investigations: a French prospective study with multidisciplinary collaboration. Forensic Sci Int Genet. 2026;81:103375.
63. Federici G, Soddu S. Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers. J Exp Clin Cancer Res. 2020;39:46.
65. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24.
66. Biesecker LG, Harrison SM. The ACMG/AMP reputable source criteria for the interpretation of sequence variants. Genet Med. 2018;20:1687-8.
67. Caroselli S, Corona G, Fabiani M, et al. Reclassification of VUS Using ACMG/AMP criteria adapted for sarcomeric genes related to hypertrophic cardiomyopathy: resolution rate and considerations. Hum Mutat. 2025;2025:6500093.
68. Neves R, Tester DJ, Simpson MA, Behr ER, Ackerman MJ, Giudicessi JR. Exome sequencing highlights a potential role for concealed cardiomyopathies in youthful sudden cardiac death. Circ-Genom Precis Me. 2022;15:e003497.
69. Girolami F, Spinelli V, Maurizi N, et al. Genetic characterization of juvenile sudden cardiac arrest and death in Tuscany: the ToRSADE registry. Front Cardiovasc Med. 2022;9:1080608.
70. Scheiper-Welling S, Tabunscik M, Gross TE, et al. Variant interpretation in molecular autopsy: a useful dilemma. Int J Legal Med. 2022;136:475-82.
71. Doldi F, Willy K, Wolfes J, et al. Changing antiarrhythmic drug regimen in patients with amiodarone and ablation refractory ventricular tachyarrhythmias is associated with increased implantable cardioverter defibrillator shocks - a retrospective analysis from a large tertiary center. JCM. 2025;14:2859.
72. Strande NT, Riggs ER, Buchanan AH, et al. Evaluating the Clinical Validity of Gene-Disease Associations: an evidence-based framework developed by the clinical genome resource. Am J Hum Genet. 2017;100:895-906.
73. Rehm HL, Berg JS, Brooks LD, et al. ClinGen - the clinical genome resource. N Engl J Med. 2015;372:2235-42.
74. Hosseini SM, Kim R, Udupa S, et al. ; On behalf of the National Institutes of Health Clinical Genome Resource Consortium. Reappraisal of reported genes for sudden arrhythmic death: evidence-based evaluation of gene validity for Brugada syndrome. Circulation. 2018;138:1195-205.
75. Adler A, Novelli V, Amin AS, et al. An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome. Circulation. 2020;141:418-28.
76. Walsh R, Adler A, Amin AS, et al. Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. Eur Heart J. 2022;43:1500-10.
77. James CA, Jongbloed JD, Hershberger RE, et al. International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the clinical genome resource framework. Circ-Genom Precis Me. 2021;14:e003273.
78. Ingles J, Goldstein J, Thaxton C, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ-Genom Precis Me. 2019;12:e002460.
79. Hespe S, Waddell A, Asatryan B, et al. Genes associated with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2025;85:727-40.
80. Jordan E, Peterson L, Ai T, et al. Evidence-based assessment of genes in dilated cardiomyopathy. Circulation. 2021;144:7-19.
81. Tsuji-Wakisaka K, Akao M, Ishii TM, et al. Identification and functional characterization of KCNQ1 mutations around the exon 7-intron 7 junction affecting the splicing process. Biochim Biophys Acta Mol Basis Dis. 2011;1812:1452-9.
82. Kanters JK, Larsen LA, Orholm M, et al. Novel donor splice site mutation in the KVLQT1 gene is associated with long QT syndrome. J Cardiovasc Electrophysiol. 2007;9:620-4.
83. Piippo K, Swan H, Pasternack M, et al. A founder mutation of the potassium channel KCNQ1 in long QT syndrome. J Am Coll Cardiol. 2001;37:562-8.
84. Aromolaran AS, Subramanyam P, Chang DD, Kobertz WR, Colecraft HM. LQT1 mutations in KCNQ1 C-terminus assembly domain suppress IKs using different mechanisms. Cardiovasc Res. 2014;104:501-11.
85. Zhang Y, Zhou N, Jiang W, et al. A missense mutation (G604S) in the S5/pore region of HERG causes long QT syndrome in a Chinese family with a high incidence of sudden unexpected death. Eur J Pediatr. 2006;166:927-33.
86. Huo J, Zhang Y, Huang N, et al. The G604S-hERG mutation alters the biophysical properties and exerts a dominant-negative effect on expression of hERG channels in HEK293 cells. Pflugers Arch - Eur J Physiol. 2008;456:917-28.
87. Sanguinetti MC, Curran ME, Spector PS, Keating MT. Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci USA. 1996;93:2208-12.
88. Crimmins S, Vashit S, Doyle L, Harman C, Turan O, Turan S. A multidisciplinary approach to prenatal treatment of congenital long QT syndrome. J Clin Ultrasound. 2016;45:168-70.
89. Zarraga IG, Zhang L, Stump MR, Gong Q, Vincent GM, Zhou Z. Nonsense-mediated mRNA decay caused by a frameshift mutation in a large kindred of type 2 long QT syndrome. Heart Rhythm. 2011;8:1200-6.
90. Hu D, Li Y, Zhang J, et al. The phenotypic spectrum of a mutation hotspot responsible for the short QT Syndrome. JACC Clin Electrophysiol. 2017;3:727-43.
91. Sun Y, Quan X, Fromme S, et al. A novel mutation in the KCNH2 gene associated with short QT syndrome. J Mol Cell Cardiol. 2011;50:433-41.
92. Corona-Rivera JR, Barrios-Prieto E, Nieto-García R, et al. Unusual retrospective prenatal findings in a male newborn with Timothy syndrome type 1. Eur J Med Genet. 2015;58:332-5.
93. Splawski I, Timothy KW, Sharpe LM, et al. CaV1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119:19-31.
94. Santos LF, Rodrigues B, Moreira D, et al. Criteria to predict carriers of a novel SCN5A mutation in a large Portuguese family affected by the Brugada syndrome. Europace. 2012;14:882-8.
95. Selga E, Campuzano O, Pinsach-Abuin M, et al. Comprehensive genetic characterization of a Spanish Brugada syndrome cohort. PLoS ONE. 2015;10:e0132888.
96. Probst V, Wilde AA, Barc J, et al. SCN5A mutations and the role of genetic background in the pathophysiology of Brugada syndrome. Circ Cardiovasc Genet. 2009;2:552-7.
97. Keller D, Rougier J, Kucera J, et al. Brugada syndrome and fever: genetic and molecular characterization of patients carrying mutations. Cardiovasc Res. 2005;67:510-9.
98. Makita N, Behr E, Shimizu W, et al. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Investig. 2008:JCI34057.
99. Okata S, Yuasa S, Suzuki T, et al. Embryonic type Na+ channel β-subunit, SCN3B masks the disease phenotype of Brugada syndrome. Sci Rep. 2016;6:34198.
100. Josephs K, Patel K, Janson CM, Montagna C, Mcdonald TV. Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia. Mol Genet Genomic Med. 2017;5:788-94.
101. Li Q, Guo R, Gao L, et al. CASQ2 variants in Chinese children with catecholaminergic polymorphic ventricular tachycardia. Mol Genet Genomic Med. 2019;7:e949.
102. Lahat H, Pras E, Eldar M. A missense mutation in CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Ann Med. 2009;36:87-91.
103. Dirksen W, Lacombe V, Chi M, et al. A mutation in calsequestrin, CASQ2D307H, impairs sarcoplasmic reticulum Ca2+ handling and causes complex ventricular arrhythmias in mice. Cardiovasc Res. 2007;75:69-78.
104. Shimamoto K, Sumitomo N, Nabeshima T, et al. Novel compound heterozygous variants in trans-2,3-enoyl-coenzyme a reductase-like gene associated with catecholaminergic polymorphic ventricular tachycardia. JACC: Case Reports. 2024;29:102364.
105. Bailey C, Blair E, Garratt C, Newman WG. Effective cascade screening through identification of a mutation in RYR2 in a large family with a history of sudden death. J Cardiol Cases. 2016;13:9-13.
106. Arad M, Glikson M, El-Ani D, Monserrat-Inglesias L. A family with recurrent sudden death and no clinical clue. Ann Noninvasive Electrocardiol. 2012;17:387-93.
107. Rabbani B, Khorgami M, Dalili M, Zamani N, Mahdieh N, Gollob MH. Novel cases of pediatric sudden cardiac death secondary to TRDN mutations presenting as long QT syndrome at rest and catecholaminergic polymorphic ventricular tachycardia during exercise: The TRDN arrhythmia syndrome. Am J Med Genet A. 2021;185:3433-45.
108. Al-Hassnan ZN, Al-Fayyadh M, Al-Ghamdi B, et al. Clinical profile and mutation spectrum of long QT syndrome in Saudi Arabia: the impact of consanguinity. Heart Rhythm. 2017;14:1191-9.
109. Vanoye CG, Desai RR, Fabre KL, et al. High-throughput functional evaluation ofKCNQ1 decrypts variants of unknown significance. Circ-Genom Precis Me. 2018;11:e002345.
110. Roberts JD, Krahn AD, Ackerman MJ, et al. Loss-of-function KCNE2 variants: true monogenic culprits of long-QT syndrome or proarrhythmic variants requiring secondary provocation? Circ-Arrhythmia Elec. 2017;10:e005282.
111. Bains S, Dotzler SM, Krijger C, et al. A phenotype-enhanced variant classification framework to decrease the burden of missense variants of uncertain significance in type 1 long QT syndrome. Heart Rhythm. 2022;19:435-42.
112. Brewer KR, Vanoye CG, Huang H, et al. Integrative analysis of KCNQ1 variants reveals molecular mechanisms of type 1 long QT syndrome pathogenesis. Proc Natl Acad. Sci USA. 2025;122:e2412971122.
113. Barsheshet A, Goldenberg I, O-Uchi J, et al. Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation. 2012;125:1988-96.
114. Wang Z, Tristani-Firouzi M, Xu Q, Lin M, Keating M, Sanguinetti M. Functional effects of mutations in KvLQT1 that cause long QT syndrome. J Cardiovasc Electrophysiol. 2007;10:817-26.
115. Giudicessi JR, Ackerman MJ. Prevalence and potential genetic determinants of sensorineural deafness in KCNQ1 homozygosity and compound heterozygosity. Circ Cardiovasc Genet. 2013;6:193-200.
116. Westphal DS, Burkard T, Moscu-Gregor A, Gebauer R, Hessling G, Wolf CM. Reclassification of genetic variants in children with long QT syndrome. Mol Genet Genomic Med. 2020;8:e1300.
117. Mak CM, Chen SP, Mok N, et al. ; Chemical Pathology Laboratory, Kowloon West Cluster Laboratory Genetic Service, Department of Pathology, Princess Margaret Hospital, Laichikok, Hong Kong. Genetic basis of channelopathies and cardiomyopathies in Hong Kong Chinese patients: a 10-year regional laboratory experience. Hong Kong Med J. 2018.
118. Koponen M, Marjamaa A, Hiippala A, et al. Follow-up of 316 molecularly defined pediatric long-qt syndrome patients: clinical course, treatments, and side effects. Circ-Arrhythmia Elec. 2015;8:815-23.
119. Ackerman MJ, Tester DJ, Porter CJ. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc. 1999;74:1088-94.
120. Cuneo BF, Etheridge SP, Horigome H, et al. Arrhythmia phenotype during fetal life suggests long-QT syndrome genotype: risk stratification of perinatal long-QT syndrome. Circ-Arrhythmia Elec. 2013;6:946-51.
121. Jons C, O-Uchi J, Moss AJ, et al. Use of mutant-specific ion channel characteristics for risk stratification of long QT syndrome patients. Sci Transl Med. 2011;3.
122. Bianchi L, Priori SG, Napolitano C, et al. Mechanisms of I(Ks) suppression in LQT1 mutants. Am J Physiol-Heart C. 2000;279:H3003-11.
123. Sacco MA, Mastrangelo H, Neri G, Aquila I. Post-mortem biomarkers in sudden cardiac death: from classical biochemistry to molecular autopsy and multi-omics forensic approaches. Int J Mol Sci. 2026;27:670.
124. Krasny L, Bland P, Kogata N, et al. SWATH mass spectrometry as a tool for quantitative profiling of the matrisome. J Proteomics. 2018;189:11-22.
125. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;11:O111.016717.
126. Chantada-Vázquez MDP, Bravo SB, Barbosa-Gouveia S, Alvarez JV, Couce ML. Proteomics in inherited metabolic disorders. Int J Mol Sci. 2022;23:14744.
127. Elmiger MP, Poetzsch M, Steuer AE, Kraemer T. Assessment of simpler calibration models in the development and validation of a fast postmortem multi-analyte LC-QTOF quantitation method in whole blood with simultaneous screening capabilities using SWATH acquisition. Anal Bioanal Chem. 2017;409:6495-508.
128. Sacco MA, Gualtieri S, Grimaldi G, et al. The role of cardiac troponins in postmortem diagnosis of myocardial ischemia: a systematic review. Int J Mol Sci. 2024;26:105.
129. Aydin S, Ugur K, Aydin S, Sahin İ, Yardim M. Biomarkers in acute myocardial infarction: current perspectives. Vasc Health Risk Manag..
130. Netala VR, Hou T, Wang Y, Zhang Z, Teertam SK. Cardiovascular biomarkers: tools for precision diagnosis and prognosis. Int J Mol Sci. 2025;26:3218.
131. Ghormade PS, Kumar NB, Tingne CV, Keoliya AN. Distribution & diagnostic efficacy of cardiac markers CK-MB & LDH in pericardial fluid for postmortem diagnosis of ischemic heart disease. J Forensic Leg Med. 2014;28:42-6.
132. Chen J, Inamori-Kawamoto O, Michiue T, Ikeda S, Ishikawa T, Maeda H. Cardiac biomarkers in blood, and pericardial and cerebrospinal fluids of forensic autopsy cases: a reassessment with special regard to postmortem interval. Leg Med. 2015;17:343-50.
133. Wang P, Yue Q. Application of IMA and H-FABP in forensic diagnosis of sudden cardiac death. Fa Yi Xue Za Zhi. 2017;33:393-6.
134. Zaborska B, Sygitowicz G, Smarż K, Pilichowska-Paszkiet E, Budaj A. Galectin-3 is related to right ventricular dysfunction in heart failure patients with reduced ejection fraction and may affect exercise capacity. Sci Rep. 2020;10:16682.
135. Zaborska B, Sikora-frąc M, Smarż K, et al. The role of galectin-3 in heart failure - the diagnostic, prognostic and therapeutic potential - where do we stand? Int J Mol Sci. 2023;24:13111.
136. Morawiec B, Kawecki D, Ho L, Tat LC, Muller O, Nowalany-Kozielska E. COPeptin for diagnosis and prediction in Acute Coronary Syndrome (COPACS) study: design and objectives. pwki. 2016;4:360-3.
137. Lin X, Lin Z, Zhao X, et al. Serum SELENBP1 and VCL are effective biomarkers for clinical and forensic diagnosis of coronary artery spasm. Int J Mol Sci. 2022;23:13266.
138. Tojo M, Shintani-Ishida K, Tsuboi H, Nakamura M, Idota N, Ikegaya H. Postmortem plasma pentraxin 3 is a useful marker of fatal acute coronary syndrome. Sci Rep. 2019;9:8090.
139. Seger C, Salzmann L. After another decade: LC-MS/MS became routine in clinical diagnostics. Clin Biochem. 2020;82:2-11.
140. Garg U, Zhang YV. Mass spectrometry in clinical laboratory: applications in biomolecular analysis. In: Garg U, Editors. Clinical applications of mass spectrometry in biomolecular analysis. New York, NY: Springer New York; 2016. pp. 1-9.
141. Martins AMA, Paiva MUB, Paiva DVN, et al. Innovative approaches to assess intermediate cardiovascular risk subjects: a review from clinical to metabolomics strategies. Front Cardiovasc. Med. 2021;8:788062.
142. Jung JY, Lee H, Kang D, et al. 1H-NMR-based metabolomics study of cerebral infarction. Stroke. 2011;42:1282-8.
143. Shirley R, Ord E, Work L. Oxidative stress and the use of antioxidants in stroke. Antioxidants. 2014;3:472-501.
144. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD. Targeting fatty acid and carbohydrate oxidation - a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta Mol Cell Res. 2011;1813:1333-50.
145. Szeremeta M, Pietrowska K, Niemcunowicz-Janica A, Kretowski A, Ciborowski M. Applications of metabolomics in forensic toxicology and forensic medicine. Int J Mol Sci. 2021;22:3010.
146. Liu P, Li R, Antonov AA, et al. Discovery of metabolite biomarkers for acute ischemic stroke progression. J Proteome Res. 2017;16:773-9.
147. Kimberly WT, Wang Y, Pham L, Furie KL, Gerszten RE. Metabolite profiling identifies a branched chain amino acid signature in acute cardioembolic stroke. Stroke. 2013;44:1389-95.
148. Căținaș R, Hostiuc S. The Latest Advances in omics technology for assessing tissue damage: implications for the study of sudden cardiac death. Int J Mol Sci. 2025;26:6818.
149. Stopa V, Lileikyte G, Bakochi A, et al. Multiomic biomarkers after cardiac arrest. ICMx. 2024;12:83.
150. Galal A, Talal M, Moustafa A. Applications of machine learning in metabolomics: Disease modeling and classification. Front Genet. 2022;13:1017340.
151. Santisukwongchote K, Amornlertwatana Y, Sastraruji T, Jaikang C. Possible use of blood tryptophan metabolites as biomarkers for coronary heart disease in sudden unexpected death. Metabolites. 2019;10:6.
152. Loretz N, Becker C, Hochstrasser S, et al. Activation of the kynurenine pathway predicts mortality and neurological outcome in cardiac arrest patients: a validation study. J Crit Care. 2022;67:57-65.
153. Lv J, Pan C, Cai Y, et al. Plasma metabolomics reveals the shared and distinct metabolic disturbances associated with cardiovascular events in coronary artery disease. Nat Commun. 2024;15:5729.
154. Ma X, Sun C, Wang T, et al. A preliminary study on cause‑of‑death discrimination and the pathological stage identification in acute ischemia heart disease (AIHD) based on plasma lipidomic technique and machine learning algorithms. Int J Legal Med. 2025;139:2621-32.
155. Radaelli D, Concato M, Bruscagin T, Sinagra G, Stornaiuolo M, D’Errico S. Lipidomic profiling of hyperacute ischemic heart disease and toxic deaths: a forensic investigation into metabolic biomarkers. Int J Mol Sci. 2025;26:9031.
156. Ward LJ, Kling S, Engvall G, et al. Postmortem metabolomics as a high-throughput cause-of-death screening tool for human death investigations. iScience. 2024;27:109794.
157. Bernini Di Michele A, Onofri V, Pesaresi M, Turchi C. The role of miRNA expression profile in sudden cardiac death cases. Genes. 2023;14:1954.
158. Li LL, Zhao ZQ. The role and significance of microRNA in human cardiovascular disease and forensic science. Fa Yi Xue Za Zhi. 2013;29:39-42.(in Chinese).
159. Yan F, Chen Y, Ye X, et al. miR-3113-5p, miR-223-3p, miR-133a-3p, and miR-499a-5p are sensitive biomarkers to diagnose sudden cardiac death. Diagn Pathol. 2021;16:67.
160. Li L, He X, Liu M, Yun L, Cong B. Diagnostic value of cardiac miR-126-5p, miR-134-5p, and miR-499a-5p in coronary artery disease-induced sudden cardiac death. Front Cardiovasc Med. 2022;9:944317.
161. Singh P, Ali W, Sandhu S, et al. Post-mortem interval estimation using miRNAs of road traffic accident cases: a forensic molecular approach. Sci Justice. 2023;63:485-92.
162. Ma XN, Lu L, Huang YT, et al. Research progress of exosomal microRNA in cardiovascular disease and its forensic application prospects. Fa Yi Xue Za Zhi. 2022;38:258-62.
163. Edston E, Kawa K. Immunohistochemical detection of early myocardial infarction. An evaluation of antibodies against the terminal complement complex (C5b-9). Int J Legal Med. 1995;108:27-30.
164. Tian M, Xue J, Dai C, Jiang E, Zhu B, Pang H. CircSLC8A1 and circNFIX can be used as auxiliary diagnostic markers for sudden cardiac death caused by acute ischemic heart disease. Sci Rep. 2021;11:4695.
165. Giulian GG, Gilbert EF, Moss RL. Elevated fetal hemoglobin levels in sudden infant death syndrome. N Engl J Med. 1987;316:1122-6.
166. Vege Å, Rognum T, Scott H, Aasen A, Saugstad O. S cases have increased levels of interleukin-6 in cerebrospinal fluid. Acta Paediatr. 2008;84:193-6.
167. Buckley MG, Variend S, Walls AF. Elevated serum concentrations of β-tryptase, but not α-tryptase, in sudden infant death syndrome (SIDS). An investigation of anaphylactic mechanisms. Clin Exp Allergy. 2008;31:1696-704.
168. Duncan JR. Brainstem serotonergic deficiency in sudden infant death syndrome. JAMA. 2010;303:430.
169. Harrington CT, Hafid NA, Waters KA. Butyrylcholinesterase is a potential biomarker for sudden infant death syndrome. eBioMedicine. 2022;80:104041.
170. Haynes RL, Frelinger AL, Giles EK, et al. High serum serotonin in sudden infant death syndrome. Proc Natl Acad Sci USA. 2017;114:7695-700.
171. Opdal SH, Rognum TO, Vege Å, Saugstad OD. Hypoxanthine Levels in Vitreous Humor: a study of influencing factors in sudden infant death syndrome. Pediatr Res. 1998;44:192-6.
172. Aldridge CM, Keene KL, Normeshie CA, Mychaleckyj JC, Hauck FR. Metabolomic profiles of infants classified as sudden infant death syndrome: a case-control analysis. eBioMedicine. 2025;111:105484.
173. Osmani WA, Gallo A, Tabor M, Eilbes M, Cook-Snyder DR, Hodges MR. Repeated seizure-induced brainstem neuroinflammation contributes to post-ictal ventilatory control dysfunction. Front Physiol. 2024;15:1413479.
174. Noebels JL. Genetic and cellular mechanisms underlying SUDEP risk. In: Noebels JL, Avoli M, Rogawski MA, Vezzani A, Delgado-Escueta AV, Editors. Jasper’s basic mechanisms of the epilepsies. 5th ed. Oxford University PressNew York; 2024. pp. 1321-46.
175. Ochoa-Urrea M, Luo X, Vilella L, et al. Risk markers for sudden unexpected death in epilepsy: an observational, prospective, multicentre cohort study. The Lancet. 2025;406:1497-507.
176. Cutshaw G, Uthaman S, Hassan N, Kothadiya S, Wen X, Bardhan R. The emerging role of Raman spectroscopy as an omics approach for metabolic profiling and biomarker detection toward precision medicine. Chem Rev. 2023;123:8297-346.
177. K P S, Vadakke Matham M, Chidangil S. Recent developments in surface-enhanced Raman spectroscopy-based immuno (apta) assays for cardiac troponin detection: prospects for point-of-care applications. Biophys Rev. 2025;18:431-57.
178. Yıldırım MŞ, Akçan R. Vibrational spectroscopic techniques as a tool in diagnosis of sudden cardiac death: a systematic review. Egypt J Forensic Sci. 2025;15:37.
179. Naz M, Shafique H, Majeed MI, et al. Surface-enhanced Raman spectroscopy (SERS) for the diagnosis of acute myocardial infarction (AMI) using blood serum samples. RSC Adv. 2024;14:29151-9.
180. Huang X, Liu B, Guo S, et al. SERS spectroscopy with machine learning to analyze human plasma derived sEVs for coronary artery disease diagnosis and prognosis. Bioeng Transl Med. 2022;8:e10420.
181. Zheng P, Wu L, Raj P, et al. Multiplexed SERS detection of serum cardiac markers using plasmonic metasurfaces. Adv Sci. 2024;11:2405910.
182. Zhang T, Li B, Wuethrich A, et al. Multiplex cardiac biomarker profiling for precision coronary artery disease risk assessment using SERS with cubic core-satellite nanostructures. Anal Chem. 2025;97:14750-60.
183. Wang F, Wan H, Chen L, et al. Gemini SERS for cross-category biomarker detection and early warning of sudden cardiac death in acute coronary syndrome. ACS Nano. 2025;19:37802-14.
184. Low JSY, Teh HF, Thevarajah TM, Chang SW, Khor SM. An AI-assisted microfluidic paper-based multiplexed surface-enhanced Raman scattering (SERS) biosensor with electrophoretic removal and electrical modulation for accurate acute myocardial infarction (AMI) diagnosis and prognosis. Biosens Bioelectron. 2025;270:116949.
185. Dixon K, Bonon R, Ivander F, et al. Using machine learning and silver nanoparticle-based surface-enhanced Raman spectroscopy for classification of cardiovascular disease biomarkers. ACS Appl Nano Mater. 2023;6:15385-96.
186. Plou J, Valera PS, García I, de Albuquerque CDL, Carracedo A, Liz-Marzán LM. Prospects of surface-enhanced Raman spectroscopy for biomarker monitoring toward precision medicine. ACS photonics. 2022;9:333-50.
187. Fan Z, Li C, Cong B, Huang P. A forensic investigation of restraint stress in rats using Fourier transform infrared (FTIR) spectroscopy techniques. Microchem J. 2025;212:113212.
188. Fan Z, Li C, Sun Q, et al. Integrated analysis of restraint stress in rat serum using ATR-FTIR and Raman spectroscopy with machine learning. Spectrochim Acta A. 2025;340:126379.
189. Li X, Wan L, Ding J, et al. Investigation of biochemical alterations in the brain of db/db diabetic mice using integrated FTIR and Raman spectroscopy combined with machine learning. Spectrochim Acta A. 2026;348:127229.
190. Li X, Ding J, Fang Z, et al. FTIR spectroscopy imaging coupled with machine learning reveals biochemical changes in the brains of diabetic mice. Spectrochim Acta A. 2026;345:126835.
191. Lin H, Wang Z, Luo Y, et al. Weighted spectrochemical correlation network analysis-guided GA-PLSR: A potential spectral “fluid biopsy” approach for quantitative assessment of cardiac metabolites in diabetic cardiomyopathy. Microchem J. 2023;185:108249.
192. Dong HW, Sun Y, Qian H, et al. Research progress on postmortem changes of computed tomography imaging characteristics on corpses. Fa Yi Xue Za Zhi. 2019;35:716-20.
193. Cergan R, Taciuc IA, Dumitru M, et al. The current status of virtual autopsy using combined imaging modalities: a scoping review. JCM. 2025;14:782.
194. Tschui J, Jackowski C, Schwendener N, Schyma C, Zech WD. Post-mortem CT and MR brain imaging of putrefied corpses. Int J Legal Med. 2016;130:1061-8.
195. Jian JQ, Liu NG, Chen YJ. Research progress in virtopsy of drowning. Fa Yi Xue Za Zhi. 2019;35:328-31.
196. Grassi S, Campuzano O, Coll M, et al. Update on the diagnostic pitfalls of autopsy and post-mortem genetic testing in cardiomyopathies. Int J Mol Sci. 2021;22:4124.
197. Kimura F, Matsuo Y, Nakajima T, et al. Myocardial fat at cardiac imaging: how can we differentiate pathologic from physiologic fatty infiltration? Radiographics. 2010;30:1587-602.
198. Péporté A, Gascho D, Stamou S, et al. Evaluation of an acetated Ringer-based contrast material mixture for postmortem computed tomography angiography. Diagn Interv Imag. 2020;101:489-97.
199. Azmitia L, Grassi S, Signorelli F, et al. Post-mortem imaging of brain/spine injuries: the importance of a comprehensive forensic approach. In: Visocchi M, Editors. The funnel: from the skull base to the sacrum. Cham: Springer International Publishing; 2023. pp. 27-31.
200. Grabherr S, Egger C, Vilarino R, Campana L, Jotterand M, Dedouit F. Modern post-mortem imaging: an update on recent developments. Forensic Sci Res. 2017;2:52-64.
201. Fröhlich Knaute D, Thali MJ, Gascho D, Schweitzer W. Technical note: post mortem CT angiography of iliacofemoral arteries after cardiovascular surgery. J Forensic Radiol Imaging. 2017;9:40-3.
202. Dedouit F, Ducloyer M, Elifritz J, et al. The current state of forensic imaging - post mortem imaging. Int J Legal Med. 2025;139:1141-59.
203. Bilotta C, Perrone G, Zerbo S, et al. The multidisciplinary approach for the diagnosis of laryngohyoid lesions: a systematic literature review and meta-analysis. Clin Ter. 2023;174:97-108.
204. Jackowski C, Schwendener N, Grabherr S, Persson A. Post-mortem cardiac 3-T magnetic resonance imaging. J Am Coll Cardiol. 2013;62:617-29.
205. O’Sullivan S, Heinsen H, Grinberg LT, et al. The role of artificial intelligence and machine learning in harmonization of high-resolution post-mortem MRI (virtopsy) with respect to brain microstructure. Brain Inf. 2019;6:3.
206. Heimer J, Gascho D, Madea B, et al. Comparison of the beta-hydroxybutyrate, glucose, and lactate concentrations derived from postmortem proton magnetic resonance spectroscopy and biochemical analysis for the diagnosis of fatal metabolic disorders. Int J Legal Med. 2020;134:603-12.
207. Zoelch N, Hock A, Steuer AE, et al. In situ postmortem ethanol quantification in the cerebrospinal fluid by non-water-suppressed proton MRS. NMR Biomed. 2019;32:e4081.
208. Gascho D, Richter H, Karampinos DC, et al. Noninvasive in situ proton MRS in muscle tissue and bone marrow as a novel approach to identify previous freezing in a completely thawed cadaver. NMR Biomed. 2020;33:e4220.
209. Trayanova NA, Popescu DM, Shade JK. Machine learning in arrhythmia and electrophysiology. Circ Res. 2021;128:544-66.
210. Narayan SM, Rogers AJ. Can machine learning disrupt the prediction of sudden death? J Am Coll Cardiol. 2023;81:962-3.
211. Chen Y, Mancini M, Zhu X, Akata Z. Semi-supervised and unsupervised deep visual learning: a survey. IEEE Trans Pattern Anal Mach Intell. 2024;46:1327-47.
212. Lin M, Guo J, Gu Z, et al. Machine learning and multi-omics integration: advancing cardiovascular translational research and clinical practice. J Transl Med. 2025;23:388.
213. Osman J, Tan SC, Lee PY, Low TY, Jamal R. Sudden cardiac death (SCD) - risk stratification and prediction with molecular biomarkers. J Biomed Sci. 2019;26:39.
214. Greener JG, Kandathil SM, Moffat L, Jones DT. A guide to machine learning for biologists. Nat Rev Mol Cell Biol. 2021;23:40-55.
215. Drouard G, Mykkänen J, Heiskanen J, et al. Exploring machine learning strategies for predicting cardiovascular disease risk factors from multi-omic data. BMC Med Inform Decis Mak. 2024;24:116.
216. Pakpahan I, Sihombing M, Liu H, Wang M, Su Z, Fang M. Harnessing artificial intelligence for genomic variant prediction: advances, challenges, and future directions. GigaScience. 2026;15:giag004.
217. Fu X, Rabadan R. Understanding variants of unknown significance: the computational frontier. The Oncologist. 2024;29:653-7.
218. Hoffman-Andrews L. The known unknown: the challenges of genetic variants of uncertain significance in clinical practice. J Law Biosci. 2017;4:648-57.
219. Piraianu A, Fulga A, Musat CL, et al. Enhancing the evidence with algorithms: how artificial intelligence is transforming forensic medicine. Diagnostics. 2023;13:2992.
220. Alafer F. Emerging imaging technologies in forensic medicine: a systematic review of innovations, ethical challenges, and future directions. Diagnostics. 2025;15:1410.
221. Wichmann D, Heinemann A, Weinberg C, et al. Virtual autopsy with multiphase postmortem computed tomographic angiography versus traditional medical autopsy to investigate unexpected deaths of hospitalized patients: a cohort study. Ann Intern Med. 2014;160:534-41.
222. Li ZH, Liu NG, Dong HW, et al. Deep learning-based cardiac imaging data measurement and its application in diagnosis of sudden cardiac death. Fa Yi Xue Za Zhi. 2021;37:546-54.
223. Shen C, Lian C, Zhang W, et al. Large-vocabulary forensic pathological analyses via prototypical cross-modal contrastive learning. Nat Commun. 2025;16:6773.
224. Emani PS, Geradi MN, Gürsoy G, Grasty MR, Miranker A, Gerstein MB. Assessing and mitigating privacy risks of sparse, noisy genotypes by local alignment to haplotype databases. Genome Res. 2023;33:2156-73.
225. Zieger M, Scudder N. Ethical and legal reflections on secondary research using genetic data acquired for criminal investigation purposes. Forensic Sci Int. Genet. 2025;75:103178.
226. Amankwaa AO, Kupčuláková B, Randall K. Humanitarian forensics: stakeholder perspectives on the use of international kinship matching DNA databases. J Forensic Leg Med. 2025;116:103018.
227. Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. Bioinformatics. 2015;31:761-3.
228. Sundaram L, Gao H, Padigepati SR, et al. Predicting the clinical impact of human mutation with deep neural networks. Nat Genet. 2018;50:1161-70.
229. Zhou J, Troyanskaya OG. Predicting effects of noncoding variants with deep learning-based sequence model. Nat Methods. 2015;12:931-4.
230. Kelley DR, Reshef YA, Bileschi M, Belanger D, Mclean CY, Snoek J. Sequential regulatory activity prediction across chromosomes with convolutional neural networks. Genome Res. 2018;28:739-50.
231. Jaganathan K, Ersaro N, Novakovsky G, et al. Predicting expression-altering promoter mutations with deep learning. Science. 2025;389:eads7373.
232. Jaganathan K, Kyriazopoulou Panagiotopoulou S, Mcrae JF, et al. Predicting splicing from primary sequence with deep learning. Cell. 2019;176:535-548.e24.
